Story perspectives

Johnson & Johnson's Icotyde: A Game-Changer for Psoriasis Treatment

3/19/2026

Summary

Story summary

Johnson & Johnson announced that the U.S. FDA approved Icotyde, a once-daily oral pill for moderate to severe plaque psoriasis.
Icotyde is the first oral treatment to compete with injectable therapies such as Tremfya and Skyrizi.
The drug targets the IL-23 receptor.
Analysts project Icotyde could exceed $8 billion in annual sales due to its safety and effectiveness.
Johnson & Johnson is exploring Icotyde for other autoimmune conditions, including psoriatic arthritis and Crohn's disease.

1 of 1

Story summary

Johnson & Johnson announced that the U.S. FDA approved Icotyde, a once-daily oral pill for moderate to severe plaque psoriasis.
Icotyde is the first oral treatment to compete with injectable therapies such as Tremfya and Skyrizi.
The drug targets the IL-23 receptor.
Analysts project Icotyde could exceed $8 billion in annual sales due to its safety and effectiveness.
Johnson & Johnson is exploring Icotyde for other autoimmune conditions, including psoriatic arthritis and Crohn's disease.